

REMARKS

Applicant's counsel thanks the Examiner for the careful consideration given the application.

The specification and claims have been amended to correct the mis-translated terms *peptido-nucleic*, *antigen*, and *exone* to the correct terms *peptide nucleic*, *anti-gene*, and *exon*. The Title has also been amended to reflect the correct terminology. In the specification, a brief description of Figs. 1 and 2 which had been missing has been inserted. The basis for inserting said description of Fig. 1 can be found on page 12 and the basis for inserting said description of Fig. 2 can be found on pages 13-14. No new matter has been added.

In response to the Examiner's suggestion, claims 10-12 have been amended to change the use claims to method claims. No new matter has been added. Regarding the applicant's IDS, copies of the references were not enclosed because they were previously sent by the IB to the USPTO; they must have gotten lost in transition or been misplaced; in any event, applicant is enclosing herewith copies of the eight references so that they may be considered by the Examiner. Applicant requests that an initialed copy of the Form PTO-1449 previously submitted be enclosed with the next communication.

In response to the restriction requirement, applicant hereby elects the invention of Group I, being claims 1-9 and 13-17. Applicant elects the species PKKKRKV. It is believed that claims 1-17 read on the elected species.

In response to the Examiner's requirements under 37 CFR 1.821 to 1.825, applicant is enclosing a paper copy of the sequence listing.

If any additional fees are required by this communication, please charge such fees to our Deposit Account No. 16-0820, Order No. BUG5-38919.

Respectfully submitted,
PEARNE & GORDON LLP

By John P. Murtaugh
John P. Murtaugh, Reg. No. 34226

1801 East 9th Street, Suite 1200
Cleveland, Ohio 44114-3108
Phone: (216) 579-1700 Fax: (216) 579-6073

Date: June 23, 2008